» Articles » PMID: 26963510

Blockade of Thrombopoietin Reduces Organ Damage in Experimental Endotoxemia and Polymicrobial Sepsis

Overview
Journal PLoS One
Date 2016 Mar 11
PMID 26963510
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Thrombopoietin (TPO), a growth factor primarily involved in thrombopoiesis may also have a role in the pathophysiology of sepsis. In patients with sepsis, indeed, TPO levels are markedly increased, with disease severity being the major independent determinant of TPO concentrations. Moreover, TPO increases and correlates with ex vivo indices of platelet activation in patients with burn injury upon sepsis development, and may contribute to depress cardiac contractility in septic shock. Still, the role of TPO in sepsis pathophysiology remains controversial, given the protective role of TPO in other experimental disease models, for instance in doxorubicin-induced cardiotoxicity and myocardial ischemia/reperfusion injury. The aim of our study was to define the contribution of TPO in the development of organ damage induced by endotoxemia or sepsis, and to investigate the effects of inhibiting TPO in these conditions.

Methods: We synthesized a chimeric protein able to inhibit TPO, mTPOR-MBP, and studied its effect in two murine experimental models, acute endotoxemia and cecal ligation and puncture (CLP) model.

Results: In both models, TPO levels markedly increased, from 289.80±27.87 pg/mL to 465.60±45.92 pg/mL at 3 hours in the LPS model (P<0.01), and from 265.00±26.02 pg/mL to 373.70±26.20 pg/mL in the CLP model (P<0.05), respectively. Paralleling TPO levels, also platelet-monocyte aggregates increased, from 32.86±2.48% to 46.13±1.39% at 3 hours in the LPS model (P<0.01), and from 43.68±1.69% to 56.52±4.66% in the CLP model (P<0.05). Blockade of TPO by mTPOR-MBP administration reduced histological damage in target organs, namely lung, liver, and gut. In particular, neutrophil infiltration and lung septal thickening were reduced from a score of 1.86±0.34 to 0.60±0.27 (P<0.01) and from 1.43±0.37 to 0.40±0.16 (P<0.05), respectively, in the LPS model at 3 hours, and from a score of 1.75±0.37 to 0.38±0.18 (P<0.01) and from 1.25±0.31 to 0.13±0.13 (P<0.001), respectively, in the CLP model. Similarly, the number of hepatic microabscesses was decreased from 14.14±1.41 to 3.64±0.56 in the LPS model at 3 hours (P<0.001), and from 1.71±0.29 to 0.13±0.13 in the CLP model (P<0.001). Finally, the diameter of intestinal villi decreased from 90.69±3.95 μm to 70.74±3.60 μm in the LPS model at 3 hours (P<0.01), and from 74.29±4.29 μm to 57.50±1.89 μm in the CLP model (P<0.01). This protective effect was associated with the blunting of the increase in platelet-monocyte adhesion, and, on the contrary, with increased platelet-neutrophil aggregates in the circulation, which may be related to decreased neutrophil sequestration into the inflamed tissues. Conversely, circulating cytokine levels were not significantly changed, in both models, by mTPOR-MBP administration.

Conclusion: Our results demonstrate that TPO participates in the development of organ damage induced by experimental endotoxemia or polymicrobial sepsis via a mechanism involving increased platelet-leukocyte adhesion, but not cytokine release, and suggest that blocking TPO may be useful in preventing organ damage in patients affected by systemic inflammatory response or sepsis.

Citing Articles

The Correlation of Hemostatic Parameters with the Development of Early Sepsis-Associated Encephalopathy. A Retrospective Observational Study.

Scarlatescu F, Scarlatescu E, Tomescu D, Bartos D J Crit Care Med (Targu Mures). 2025; 10(4):329-336.

PMID: 39829725 PMC: 11740703. DOI: 10.2478/jccm-2024-0040.


Differential neutrophil responses in murine following intraperitoneal injections of and .

Zhu Y, Luo J, Xia X, Feng H, Zhao P Heliyon. 2024; 10(22):e40281.

PMID: 39641065 PMC: 11617748. DOI: 10.1016/j.heliyon.2024.e40281.


Cathelicidin-HG Alleviates Sepsis-Induced Platelet Dysfunction by Inhibiting GPVI-Mediated Platelet Activation.

Xiong W, Chai J, Wu J, Li J, Lu W, Tian M Research (Wash D C). 2024; 7:0381.

PMID: 38840901 PMC: 11151873. DOI: 10.34133/research.0381.


Extract Inhibits Platelet Desialylation and Activation to Ameliorate Sepsis-Associated Thrombocytopenia in a Murine CLP-Induced Sepsis Model.

Jeong S, Park J, Ryu Y, Kim W, Lee I, Kim J Int J Mol Sci. 2023; 24(10).

PMID: 37240208 PMC: 10218882. DOI: 10.3390/ijms24108863.


Correlation between thrombopoietin and inflammatory factors, platelet indices, and thrombosis in patients with sepsis: A retrospective study.

Xu W, Mo L, Shi M, Rao H, Zhan X, Yang M World J Clin Cases. 2022; 10(13):4072-4083.

PMID: 35665097 PMC: 9131241. DOI: 10.12998/wjcc.v10.i13.4072.


References
1.
Wolber E, Jelkmann W . Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B. J Interferon Cytokine Res. 2000; 20(5):499-506. DOI: 10.1089/10799900050023915. View

2.
De Blasi R, Cardelli P, Costante A, Sandri M, Mercieri M, Arcioni R . Immature platelet fraction in predicting sepsis in critically ill patients. Intensive Care Med. 2012; 39(4):636-43. DOI: 10.1007/s00134-012-2725-7. View

3.
Akca S, Haji-Michael P, De Mendonca A, Suter P, Levi M, Vincent J . Time course of platelet counts in critically ill patients. Crit Care Med. 2002; 30(4):753-6. DOI: 10.1097/00003246-200204000-00005. View

4.
Angus D, van der Poll T . Severe sepsis and septic shock. N Engl J Med. 2013; 369(9):840-51. DOI: 10.1056/NEJMra1208623. View

5.
Zou L, Feng Y, Li Y, Zhang M, Chen C, Cai J . Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis. J Immunol. 2013; 191(11):5625-35. PMC: 3906719. DOI: 10.4049/jimmunol.1301903. View